BioStock: Aptahem’s CEO looks forward to an exciting second half of the year

During 2021, sepsis company Aptahem has taken several steps to prepare for its first clinical evaluation of its leading drug candidate Apta-1. Ahead of the phase I studies that are expected to begin next year, the company has so far this year received the preliminary approval of patents pertaining to family two in Europe and the USA. Together with Örebro University, the company has also identified a mechanism of action has at the molecular level for the drug candidate. BioStock spoke with CEO Mikael Lindstam about the past six months and what he expects from the second half of the year.

Read the interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/aptahems-ceo-looks-forward-to-an-exciting-second-half-of-the-year/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se